ARTICLE | Finance
Oncolytic cash infusion
Why PsiOxus plans to use series C for preclinical oncolytic viruses
June 1, 2015 7:00 AM UTC
Despite having a Phase III-ready asset in cancer cachexia, PsiOxus Therapeutics Ltd. plans to use all of its series C round on developing its earlier stage oncolytic virus programs.
PsiOxus raised £25 million ($39.2 million) in a round led by existing investor Imperial Innovations Group plc (LSE:IVO), which invested £7 million ($11 million). Existing investors Invesco, SROne, Lundbeckfond Ventures and Mercia Technologies also participated, as did new investor Woodford Investment Management through its Woodford Patient Capital Trust fund. ...